Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03726125 | A Study of LY3374849 in Healthy Participants | PHASE1 | COMPLETED | 89 | — | — | Nov 20, 2018 | Sep 27, 2019 | Oct 17, 2019 | 1 | Singapore |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3374849 - SC (Part A) | EXPERIMENTAL | Single subcutaneous (SC) dose of LY3374849 |
| Insulin Degludec - SC (Part A) | EXPERIMENTAL | Single SC dose of insulin degludec |
| LY3374849 - SC (Part B) | EXPERIMENTAL | Single dose of LY3374849 administered SC in up to three of three study periods |
| LY3374849 - IV (Part B) | EXPERIMENTAL | Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods |
| LY3374849 - IV (Part C) | EXPERIMENTAL | Single IV dose of LY3374849 in one of two study periods |
| Insulin Degludec - IV (Part C) | EXPERIMENTAL | Single IV dose of insulin degludec in one of two study periods |
| Name | Type | Description |
|---|---|---|
| LY3374849 - SC | DRUG | Administered SC |
| Insulin Degludec - SC | DRUG | Administered SC |
| LY3374849 - IV | DRUG | Administered IV |
| Insulin Degludec - IV | DRUG | Administered IV |
Inclusion Criteria: * Healthy male or a female who cannot become pregnant * Have a body mass index (BMI) of at least 18 kilogram per square meter (kg/m²) * Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study * Ha...